ArticleCancers2023

Cell-of-Origin Targeted Drug Repurposing for Triple-Negative and Inflammatory Breast Carcinoma with HDAC and HSP90 Inhibitors Combined with Niclosamide.

Udayan Bhattacharya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.